Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Shire    SHP   JE00B2QKY057

Mes dernières consult.
Most popular
Delayed Quote. Delayed  - 05/25 05:35:20 pm
4133.5 GBp   +0.74%
05/25SHIRE : Form 8.5 (EPT/RI)- Shire plc AMENDMENT
05/25SHIRE : Form 8.5 (EPT/RI) - Replacement of Shire plc
05/25SHIRE : Form 8.5 SHIRE PLC
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Shire Plc. : Shire Buying Pervasis To Advance Regenerative Medicines Business

share with twitter share with LinkedIn share with facebook
share via e-mail
04/12/2012 | 05:49pm CEST
  By Sten Stovall 

Shire PLC (SHP.LN) is buying the assets of U.S.-based Pervasis Therapeutics in a deal that brings a new technology aimed at improving blood vessel repair for dialysis patients to the U.K. drug maker's regenerative medicine business.

A specialist in hyperactivity and rare genetic diseases, Shire is also expanding its activities in regenerative medicine to find products for replacing human cells, tissues or organs to restore or establish normal function.

Toward that end, Shire on Thursday said it will pay Pervasis an undisclosed upfront payment, plus milestones if Pervasis' lead product, a cell-based therapy called Vascugel, hits certain clinical, regulatory and sales targets. No financial terms were disclosed.

Pervasis, based in Cambridge, Massachusetts, is developing acute vascular repair technologies for patients with end-stage renal disease, or ESRD, which is an advanced and irreversible kidney disease. There are around 600,000 people in the U.S. and more than 250,000 in the EU currently being treated for ESRD.

Shire said its deal with Pervasis will make a strong strategic fit with its existing Dermagraft treatment for diabetic foot ulcers.

Diabetes is the chief cause of ESRD, while diabetic patients on dialysis have a greater risk of developing a diabetic foot ulcer than diabetics not receiving dialysis treatment.

Shire's head of regenerative medicine, Kevin Rakin, said that "this acquisition marks a very important step for Shire in building a regenerative medicine business focused on tissue repair and regeneration."

He told Dow Jones Newswires that Vascugel is currently in mid-stage clinical trials and will be progressing to late-stage Phase III testing soon. Vascugel has received Orphan Product designation from the U.S. Food and Drug Administration and from the European Medical Agency. If all goes well, marketing authorization could be sought for Vascugel by 2017, Rakin said.

Pervasis will give Shire a new cell-based technology platform called endothelial cell technology that has global potential. "We are looking at generating other products out of this platform," Rakin said.

"We're building our regenerative medicine activities because we believe it's one of the next big areas of medicine and so this adds to the Dermagraft purchase and we're building up our pipeline now. We're committed to doing this."

- By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SHIRE
05/25SHIRE : Form 8.5 (EPT/RI)- Shire plc AMENDMENT
05/25SHIRE : Form 8.5 (EPT/RI) - Replacement of Shire plc
05/25SHIRE : Form 8.5 SHIRE PLC
05/25SHIRE : Form 8.5 (EPT/NON-RI)- Shire Plc
05/25SHIRE : Form 8.5 (EPT/RI)- Shire plc
05/25SHIRE : Form 8.5 (EPT/RI) - SHIRE PLC
05/25SHIRE : Form 8.3 - Shire PLC
05/25SHIRE : Form 8.5 (EPT/RI)
05/24SHIRE PLC : Other Events, Financial Statements and Exhibits (form 8-K)
05/24SHIRE : Director Declaration
More news
News from SeekingAlpha
05/25Shire/Takeda Merger - Classical Destruction Of Value 
05/25Tracking Larry Robbins' Glenview Capital Management Portfolio - Q1 2018 Updat.. 
05/223Pea Is A Payment Processor With >40% Organic Growth Selling For Half Of Peer.. 
05/22Shire's Vonvendi shows treatment benefit in late-stage study 
05/18Tracking John Paulson's Paulson & Co. Portfolio - Q1 2018 Update 
Financials ($)
Sales 2018 15 453 M
EBIT 2018 5 701 M
Net income 2018 2 931 M
Debt 2018 15 061 M
Yield 2018 0,67%
P/E ratio 2018 17,52
P/E ratio 2019 14,64
EV / Sales 2018 4,21x
EV / Sales 2019 3,85x
Capitalization 50 044 M
Duration : Period :
Shire Technical Analysis Chart | SHP | JE00B2QKY057 | 4-Traders
Technical analysis trends SHIRE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 61,2 $
Spread / Average Target 11%
EPS Revisions
Flemming Ornskov Chief Executive Officer & Executive Director
Susan Saltzbart Kilsby Non-Executive Chairman
Thomas J. W. Dittrich Chief Financial Officer & Director
Howard Mayer Chief Medical Officer
Matthew Walker Head-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
SHIRE5.21%50 044
JOHNSON & JOHNSON-11.45%327 893
PFIZER-1.16%209 941
NOVARTIS-6.94%193 872
ROCHE HOLDING LTD.-9.17%190 404